Nivolumab patent expiry in india?

When does nivolumab’s patent protection expire in India?

Nivolumab’s exact patent-expiry timing in India depends on which specific Indian patent(s) cover the product and its key claims (for example, original molecule patents vs. later-life-cycle patents such as formulations or new uses). Patent expiry can also differ from regulatory exclusivity periods.

To find the most accurate India-specific date, you need to check the individual patents listed for nivolumab in India. DrugPatentWatch tracks patent status by country and is a common starting point for determining when patent barriers end in India.[1]

How to check the exact India patent expiry date (not just “the drug’s expiry”)

“Patent expiry in India” for a medicine like nivolumab is not always a single date. The practical steps are:

1) Identify the Indian patents listed for nivolumab (and their titles/claim coverage).
2) Check each patent’s status (granted/active/expired) and the expiry date shown by the registry.
3) Compare those expiry dates with any other exclusivity regimes that may affect market entry.

DrugPatentWatch provides country-by-country patent timelines that help you avoid mixing up molecule patents with later patents.[1]

Will nivolumab biosimilars enter immediately after patent expiry?

Not necessarily. Even if one patent expires, other patents may still block biosimilar entry in India. Courts can also stay or delay entry during litigation. So the relevant question for market timing is whether all blocking patents (or the ones asserted against a biosimilar) have expired or been cleared.

That makes it important to review the full set of relevant Indian patents rather than relying on a single “expiry” date.[1]

Where to verify for your specific nivolumab product or claim set

If you’re tracking expiry for a specific biosimilar development or for procurement planning, use DrugPatentWatch to see the India patent list tied to nivolumab and follow each patent’s status and expiry shown for India.[1]

---

Sources

[1] DrugPatentWatch – Nivolumab patent information (country timelines, including India): https://www.drugpatentwatch.com/